Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seohyun | - |
dc.contributor.author | Kim, Seong A. | - |
dc.contributor.author | Han, Jihoon | - |
dc.contributor.author | Kim, In-San | - |
dc.date.accessioned | 2022-02-13T20:41:03Z | - |
dc.date.available | 2022-02-13T20:41:03Z | - |
dc.date.created | 2022-01-19 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/135663 | - |
dc.description.abstract | Cancer immunotherapy is fast rising as a prominent new pillar of cancer treatment, harnessing the immune system to fight against numerous types of cancer. Rho-kinase (ROCK) pathway is involved in diverse cellular activities, and is therefore the target of interest in various diseases at the cellular level including cancer. Indeed, ROCK is well-known for its involvement in the tumor cell and tumor microenvironment, especially in its ability to enhance tumor cell progression, migration, metastasis, and extracellular matrix remodeling. Importantly, ROCK is also considered to be a novel and effective modulator of immune cells, although further studies are needed. In this review article, we describe the various activities of ROCK and its potential to be utilized in cancer treatment, particularly in cancer immunotherapy, by shining a light on its activities in the immune system. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | MYOSIN LIGHT-CHAIN | - |
dc.subject | EPITHELIAL-MESENCHYMAL TRANSITION | - |
dc.subject | CELL-MIGRATION | - |
dc.subject | PROTEIN-KINASE | - |
dc.subject | ROCK-II | - |
dc.subject | HEPATOCELLULAR-CARCINOMA | - |
dc.subject | SERINE/THREONINE KINASE | - |
dc.subject | TUMOR PROGRESSION | - |
dc.subject | SIGNALING PATHWAY | - |
dc.subject | TISSUE STIFFNESS | - |
dc.title | Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, In-San | - |
dc.identifier.doi | 10.3390/ijms222312916 | - |
dc.identifier.scopusid | 2-s2.0-85120052989 | - |
dc.identifier.wosid | 000734829900001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.22, no.23 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 22 | - |
dc.citation.number | 23 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | MYOSIN LIGHT-CHAIN | - |
dc.subject.keywordPlus | EPITHELIAL-MESENCHYMAL TRANSITION | - |
dc.subject.keywordPlus | CELL-MIGRATION | - |
dc.subject.keywordPlus | PROTEIN-KINASE | - |
dc.subject.keywordPlus | ROCK-II | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | SERINE/THREONINE KINASE | - |
dc.subject.keywordPlus | TUMOR PROGRESSION | - |
dc.subject.keywordPlus | SIGNALING PATHWAY | - |
dc.subject.keywordPlus | TISSUE STIFFNESS | - |
dc.subject.keywordAuthor | Rho-kinase (ROCK) | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordAuthor | ROCK inhibitors | - |
dc.subject.keywordAuthor | tumor microenvironment (TME) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.